Intercept Pharmaceuticals, Inc. (ICPT) Rating Reiterated by Robert W. Baird

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by equities researchers at Robert W. Baird in a report released on Saturday. They currently have a $332.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price target indicates a potential upside of 439.05% from the company’s previous close.

ICPT has been the subject of a number of other reports. Laidlaw reissued a “hold” rating and set a $119.00 target price (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Cowen and Company reissued an “outperform” rating and set a $232.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. BMO Capital Markets increased their target price on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 1st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Finally, Cantor Fitzgerald reissued an “underweight” rating and set a $69.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $174.93.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 61.59 on Friday. Intercept Pharmaceuticals has a 12 month low of $60.97 and a 12 month high of $172.75. The company’s 50-day moving average is $106.75 and its 200-day moving average is $115.74. The stock’s market capitalization is $1.55 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period last year, the company posted ($3.14) EPS. Equities analysts anticipate that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Rating Reiterated by Robert W. Baird” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/25/intercept-pharmaceuticals-inc-icpt-rating-reiterated-by-robert-w-baird.html.

In other news, insider Lisa Bright sold 394 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $121.33, for a total value of $47,804.02. Following the completion of the sale, the insider now owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Mark Pruzanski sold 1,434 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $121.78, for a total value of $174,632.52. Following the completion of the sale, the chief executive officer now directly owns 570,284 shares of the company’s stock, valued at approximately $69,449,185.52. The disclosure for this sale can be found here. In the last three months, insiders sold 8,013 shares of company stock valued at $966,747. 9.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICPT. WFG Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at approximately $130,000. IFP Advisors Inc boosted its holdings in shares of Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at approximately $170,000. 82.19% of the stock is owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply